Improvement of in vivo genotoxicity assessment: Combination of acute tests and integration into standard toxicity testing
Andreas Rothfuß(Bayer (Germany)), Hans‐Jörg Martus(Beth Israel Deaconess Medical Center), Ulla Plappert‐Helbig(Novartis Institutes for BioMedical Research), Robert H. Heflich(National Center for Toxicological Research), Leslie Recio(Integrated Laboratory Systems, Inc.), Jonathan Howe(GlaxoSmithKline (United Kingdom)), Marilyn J. Aardema(Procter & Gamble (United States)), Shuichi Hamada(Mitsubishi Chemical (Japan)), Brian Burlinson, Andreas Czich(Sanofi (Germany)), Mike O’Donovan(AstraZeneca (United Kingdom)), David Kirkland(Covance (United Kingdom)), Madoka Nakajima, Yoshifumi Uno(Mitsubishi Group (Japan)), Masamitu Honma(National Institute of Health Sciences), Maik Schuler(Pfizer (United States)), Catherine Priestley(AstraZeneca (United Kingdom)), Sheila M. Galloway(United States Military Academy)
Mutation Research/Genetic Toxicology and Environmental Mutagenesis
December 22, 2010
Cited by 106
Related Papers
Chromosome aberrations and sister chromatid exchanges in chinese hamster ovary cells: Evaluations of 108 chemicals
|Environmental and Molecular Mutagenesis|1987|661
A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity
|Regulatory Toxicology and Pharmacology|2006|461
How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2007|437
Rapid accumulation of genome rearrangements in liver but not in brain of old mice
|Nature Genetics|1997|254
Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster
|Proceedings of the National Academy of Sciences|2000|221